Blood cancers

CAR T-cell therapy in DLBCL: patient selection, referral and predictive markers

Sponsored by Novartis Pharmaceuticals Australia Pty Limited

“If there’s one thing I’d like clinicians to remember, it’s not to hold back on sending through a referral for consideration of your patient with diffuse large B-cell lymphoma (DLBCL) for CAR T-cell therapy,” says Dr Jason Butler, a clinical haematologist at the bone marrow transplant unit at the Royal Brisbane and Women’s Hospital which ...

Already a member?

Login to keep reading.

© 2021 the limbic